Cargando…
The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis
The COVID-19 pandemic has hugely disrupted healthcare provision, including oncology services. To evaluate the effects of the pandemic on referral routes leading to diagnosis, treatments, and prognosis in patients with pancreatic ductal adenocarcinoma, we performed a retrospective cohort study at a s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105306/ https://www.ncbi.nlm.nih.gov/pubmed/35566700 http://dx.doi.org/10.3390/jcm11092574 |
_version_ | 1784708008151875584 |
---|---|
author | Madge, Oliver Brodey, Alexandra Bowen, Jordan Nicholson, George Sivakumar, Shivan Bottomley, Matthew J. |
author_facet | Madge, Oliver Brodey, Alexandra Bowen, Jordan Nicholson, George Sivakumar, Shivan Bottomley, Matthew J. |
author_sort | Madge, Oliver |
collection | PubMed |
description | The COVID-19 pandemic has hugely disrupted healthcare provision, including oncology services. To evaluate the effects of the pandemic on referral routes leading to diagnosis, treatments, and prognosis in patients with pancreatic ductal adenocarcinoma, we performed a retrospective cohort study at a single tertiary centre in the UK. The patients were identified from the weekly hepatopancreatobiliary multidisciplinary team meetings between February 2018 and March 2021. The demographic, referral, and treatment data for each patient and date of death, where applicable, were extracted from the electronic patient record. The patients (n = 203) were divided into “pre-pandemic” and “pandemic” cohorts based on a referral date cut-off of 23rd March 2020. The median survival was 7.4 months [4.9–9.3] in the “pre-pandemic” cohort (n = 125), halving to 3.3 months [2.2–6.0], (p = 0.015) in the “pandemic” cohort (n = 78). There was no significant difference in patient characteristics between the two cohorts. There was a trend toward increased emergency presentations at diagnosis and reduced use of surgical resection in the “pandemic” cohort. This small-scale study suggested that the COVID-19 pandemic is associated with a halving of median survival in pancreatic ductal adenocarcinoma. Urgent further studies are required to confirm these findings and examine corresponding effects in other cancer types. |
format | Online Article Text |
id | pubmed-9105306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91053062022-05-14 The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis Madge, Oliver Brodey, Alexandra Bowen, Jordan Nicholson, George Sivakumar, Shivan Bottomley, Matthew J. J Clin Med Article The COVID-19 pandemic has hugely disrupted healthcare provision, including oncology services. To evaluate the effects of the pandemic on referral routes leading to diagnosis, treatments, and prognosis in patients with pancreatic ductal adenocarcinoma, we performed a retrospective cohort study at a single tertiary centre in the UK. The patients were identified from the weekly hepatopancreatobiliary multidisciplinary team meetings between February 2018 and March 2021. The demographic, referral, and treatment data for each patient and date of death, where applicable, were extracted from the electronic patient record. The patients (n = 203) were divided into “pre-pandemic” and “pandemic” cohorts based on a referral date cut-off of 23rd March 2020. The median survival was 7.4 months [4.9–9.3] in the “pre-pandemic” cohort (n = 125), halving to 3.3 months [2.2–6.0], (p = 0.015) in the “pandemic” cohort (n = 78). There was no significant difference in patient characteristics between the two cohorts. There was a trend toward increased emergency presentations at diagnosis and reduced use of surgical resection in the “pandemic” cohort. This small-scale study suggested that the COVID-19 pandemic is associated with a halving of median survival in pancreatic ductal adenocarcinoma. Urgent further studies are required to confirm these findings and examine corresponding effects in other cancer types. MDPI 2022-05-04 /pmc/articles/PMC9105306/ /pubmed/35566700 http://dx.doi.org/10.3390/jcm11092574 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Madge, Oliver Brodey, Alexandra Bowen, Jordan Nicholson, George Sivakumar, Shivan Bottomley, Matthew J. The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis |
title | The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis |
title_full | The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis |
title_fullStr | The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis |
title_full_unstemmed | The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis |
title_short | The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis |
title_sort | covid-19 pandemic is associated with reduced survival after pancreatic ductal adenocarcinoma diagnosis: a single-centre retrospective analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105306/ https://www.ncbi.nlm.nih.gov/pubmed/35566700 http://dx.doi.org/10.3390/jcm11092574 |
work_keys_str_mv | AT madgeoliver thecovid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis AT brodeyalexandra thecovid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis AT bowenjordan thecovid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis AT nicholsongeorge thecovid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis AT sivakumarshivan thecovid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis AT bottomleymatthewj thecovid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis AT madgeoliver covid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis AT brodeyalexandra covid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis AT bowenjordan covid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis AT nicholsongeorge covid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis AT sivakumarshivan covid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis AT bottomleymatthewj covid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis |